# William G. Wierda

Source: https://onco.cc/people/william-wierda/  
OnCo record `william-wierda` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CAPTIVATE, which established fixed-duration ibrutinib plus venetoclax as a first-line option for CLL.

## Summary

William Wierda was principal investigator of CAPTIVATE, the trial showing fixed-duration ibrutinib plus venetoclax produces high rates of undetectable MRD and durable remissions in untreated CLL and led to its approval in Europe, and led the MRD-guided cohort of that study. He chairs the NCCN CLL guidelines panel and helped develop the MD Anderson prognostic nomogram for CLL.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cll; fixed-duration; guidelines
- Role: Professor and Section Chief of CLL, Department of Leukemia, MD Anderson Cancer Center
- Specialisms: Chronic lymphocytic leukaemia; Fixed-duration targeted therapy; MRD-guided treatment; Guidelines

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Wierda%20WG%5BAuthor%5D%20chronic%20lymphocytic%20leukemia

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- trials: [CAPTIVATE](https://onco.cc/trials/captivate/)

---
JSON: https://onco.cc/api/v1/entities/william-wierda.json